Navigation Links
Halozyme Announces Positive Results from Roche's Subcutaneous Herceptin Phase 3 Trial
Date:10/17/2011

SAN DIEGO, Oct. 18, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today announced that the Phase 3 HannaH trial, conducted by Roche, showed that women with HER2-positive early breast cancer who received a new, investigational subcutaneous (SC) injection of Herceptin® (trastuzumab), experienced comparable results to Herceptin given as an intravenous (IV) infusion. The SC administration takes around 5 minutes to administer whereas the IV formulation (the current standard) takes around 30 minutes to infuse. Since the subcutaneous administration is an injection under the skin it may allow patients to spend less time in hospital receiving their treatment versus the intravenous method. The ready to use formulation may also significantly reduce pharmacy time as no medicine preparation time is required.

(Logo:  http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

"We are very pleased to see this important program achieve success in a Phase 3 pivotal clinical trial," said Gregory Frost, Ph.D., Halozyme's president and CEO. "The convenience of subcutaneous administration may provide another option for women living with early breast cancer."

No new safety signals were observed and adverse events were overall consistent with Herceptin IV. Data from the trial will be submitted for presentation at an upcoming medical meeting and will support a marketing application to regulatory authorities in the European Union in 2012.

Roche has additional ongoing trials of a subcutaneous formulation of MabThera® (rituximab), using Enhanze™ Technology in pat
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer
2. Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
3. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
4. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
5. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
6. Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial
7. Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
8. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
9. Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
10. Halozyme Provides HYLENEX® Product Reintroduction Update
11. Halozyme Therapeutics Announces Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 18, 2014  KIYATEC announced today that it ... Innovation Research (SBIR) Phase II Contract from the ... institutes and centers that comprise the National Institutes ... two year award, KIYATEC will expand its 3D ... the forefront of cancer therapy strategies: 1) cancer,s ...
(Date:9/18/2014)... PLYMOUTH MEETING, Pa. , Sept. 18, ... eClinical trial solutions, was recognized as the ... 2014 for its ePharmaONE cloud-based eClinical platform. ... portal and electronic trial master file (eTMF), ... informed-consent solution, and ePharmaSolutions, ReferralPlus+ patient screening ...
(Date:9/18/2014)... , Sept. 18, 2014   3D Systems   (NYSE: ... Simbionix RobotiX Mentor™ , a new robotic surgery skills ... first time at the ERUS exhibition in Amsterdam, ... #7). Robotic-assisted minimally invasive surgery represents a growing ... the needs for training for robotic surgery has increased, and ...
Breaking Medicine Technology:National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 2National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 3ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 2ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 33D Systems Introduces New Simbionix Robotics Training Platform 23D Systems Introduces New Simbionix Robotics Training Platform 3
... BOSTON, Jan. 27, 2011 Solos Endoscopy, Inc. (OTCPK: SNDY) ... the three months ended December 31, 2010 in the amount ... a result of instrument sales to over fifty Hospitals, Clinics, ... States. Solos looks towards continued growth in 2011 ...
... /PRNewswire-Asia/ -- Weikang Bio-Technology Group Co., Inc. ... the "Company"), a leading developer, manufacturer and marketer of ... and other health and nutritional products in the People,s ... products, Ranitidine Hydrochloride Capsule, has been added to the ...
Cached Medicine Technology:Solos Endoscopy, Inc. Reports $90,005 in Sales Revenue for Fourth Quarter 2010 2Weikang Bio-Technology Announces Inclusion of Ranitidine Hydrochloride Capsule on National Drug Reimbursement List 2Weikang Bio-Technology Announces Inclusion of Ranitidine Hydrochloride Capsule on National Drug Reimbursement List 3
(Date:9/18/2014)... 2014 Memorial Cardiac and Vascular ... week by performing the first ever, adult heart transplant ... for Organ Sharing) approval to launch the adult heart ... two programs in South Florida. , The skilled ... Gongora, Medical Director of the Adult Heart Transplant ...
(Date:9/18/2014)... September 19, 2014 A jacket is ... A jacket typically has sleeves, and fastens in the ... generally lighter, tighter-fitting, and less insulating than a coat, ... serve as protective clothing. Today, Fecbek, a well-known clothing ... of trendy men’s jackets; all these items are offered ...
(Date:9/18/2014)... Sept. 18, 2014 (HealthDay News) -- Rising temperatures in ... to spread to shallow waters that are becoming warmer, ... coral reefs, ecologists report. A study of 40 ... shows northward movement by the invasive and poisonous lionfish, ... Administration (NOAA) and the University of North Carolina-Wilmington, who ...
(Date:9/18/2014)... Steven Reinberg HealthDay Reporter ... sign that the Ebola outbreak in West Africa is starting to ... more than 700 new cases of the deadly viral infection were ... of cases to more than 5,300, with roughly half of those ... reported. The number of deaths now tops 2,600. WHO has ...
(Date:9/18/2014)... 18, 2014 Limited spots remain at ... Only 100 spots are still available for Becker's ASC ... ASCs on October 23-25, 2014 at the Swissotel Chicago. ... Chief Information Officer Strategy Roundtable on November 4, 2014 ... remain for Becker's Hospital Review Chief Executive Officer Strategy ...
Breaking Medicine News(10 mins):Health News:Memorial Cardiac & Vascular Institute Performs First Adult Heart Transplant in Broward County 2Health News:Memorial Cardiac & Vascular Institute Performs First Adult Heart Transplant in Broward County 3Health News:Memorial Cardiac & Vascular Institute Performs First Adult Heart Transplant in Broward County 4Health News:Cool Jackets Are For Sale At Fecbek.com 2Health News:Rising Atlantic Ocean Temperatures Could Pose Threat to Reefs 2Health News:New Ebola Cases Top 700 in Just One Week, Officials Report 2Health News:New Ebola Cases Top 700 in Just One Week, Officials Report 3Health News:Limited Spots Remain at Becker's Upcoming ASC and Hospital Conferences 2
... for Complimentary Services and Fund Raising Program In ... 15 Westside Medical Spa today,announced the launch of "Face ... preparing to embark on a new chapter in their lives.,Structured ... the,Day" has partnered with Jenesse Center Inc., in support of ...
... - Aspreva Pharmaceuticals,Corporation (NASDAQ: ASPV ; TSX: ... of evidence-based medicines available for patients,living with less ... financial and business results for the third quarter ... Aspreva will host a conference call to discuss ...
... for Unwanted Babies, Prevents Abandonment, HARRISBURG, Pa., Oct. ... today reminded expectant,parents and parents of newborns that Pennsylvania,s ... infants, up to 28 days old, to,any hospital as ... Sharon, Mercer County, a newborn girl was found in ...
... issue of the Journal of General Internal Medicine, geriatrics researchers ... Center for Aging Research and the Regenstrief Institute, Inc. say ... adults, cannot meet the needs of the growing number of ... system approaches dementia. , We have a ...
... Comment on Role of Screening,Colonoscopy in Reducing ... Today,s news from the,CDC and American ... cancer,deaths in the United States includes heartening ... of the nation,s leading gastrointestinal,specialists are convening ...
... Obligations to Laurus Fully Repaid, LARGO, Fla., ... Board: DYHP.OB) ("Dynamic"), a leading distributor in,the sports ... it filed its Articles of Merger with the ... Nasdaq of its merger with GeoPharma, Inc.,(Nasdaq: ...
Cached Medicine News:Health News:Westside Medical Spa Launches 'Face the Day' to Aid Battered Women 2Health News:Aspreva to Announce 2007 Third Quarter Results on October 31st 2Health News:PA Department of Public Welfare Reminds New Parents About 'Safe Haven' Law 2Health News:Editorial says primary care system must change how it approaches dementia 2Health News:Dynamic Files Articles of Merger; Notifies Nasdaq of Merger with GeoPharma 2Health News:Dynamic Files Articles of Merger; Notifies Nasdaq of Merger with GeoPharma 3
... its wide orifice tip, the Finntip Wide ... suspensions and macromolecules like genomic DNA. This ... cell fragmentation. It is excellent for use ... model, the inside diameter of the orifice ...
... have been designed to optimize the accuracy ... our tip products is widely recognized by ... has been extended over the years and ... and special tips including filter tips, certified ...
MBP's equivalent to the "Universal Yellow" tip, this 200 L tip utilizes a MicroPoint design for accurate sample handling. 10 L Ref. mark....
The LH ELISA kit is used for the quantitative measurement of LH in human serum or plasma....
Medicine Products: